

Temporary Benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability for Auro-Galantamine ER 8 mg Extended-Release Capsule (DIN 02425157), Galantamine ER 8 mg Extended-Release Capsule (DIN 02443015) manufactured by Sanis Health Inc, Mylan-Galantamine ER 8 mg Extended-Release Capsule (DIN 02339439), Auro-Galantamine ER 16 mg Extended-Release Capsule (DIN 02425165), Galantamine ER 16 mg Extended-Release Capsule (DIN 02443023) manufactured by Sanis Health Inc and Mylan-Galantamine ER 16 mg Extended-Release Capsule (DIN 02339447), **PAT-Galantamine ER 16 mg Extended-Release Capsule (DIN 02316951)** will be considered a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List February 27, 2024.

As of February 27, 2024, all claims for **PAT-Galantamine ER 16 mg Extended-Release Capsule (DIN 02316951)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/provider/type/pharmacy/home.php.

Product supply shortages addressed for *ADBL*

Alberta Blue Cross has confirmed that the shortage for Pinaverium 50 mg Tablet (DIN 02469677) manufactured by AA Pharma Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 25, 2024**. The following grouping was removed from the Critical Supply Product List February 23, 2024.

PINAVERIUM BROMIDE

50 MG TABLET

00002469677	PINAVERIUM	AAP	\$ 0.3066
00001950592	DICETEL	BGP	\$ 0.3998

Alberta Blue Cross has confirmed that the shortage for Apo-Fluvoxamine 100 mg Tablet (DIN 02231330) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 25, 2024**. The following grouping was removed from the Critical Supply Product List February 23, 2024.

FLUVOXAMINE MALEATE

100 MG TABLET

00002255537	ACT FLUVOXAMINE	TEV	\$ 0.3783
00002231330	APO-FLUVOXAMINE	APX	\$ 0.3783
00001919369	LUVOX	BGP	\$ 1.8796

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Taro-Imiquimod Pump 5% Topical Cream (DIN 02482983) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 2, 2024**. The following grouping was removed from the Critical Supply Product List February 29, 2024.

IMIQUIMOD

50 MG/G / G TOPICAL CREAM

00002482983	TARO-IMIQUIMOD PUMP	TAR	\$ 43.4350
00002239505	ALDARA P	VCL	\$ 55.5780

Alberta Blue Cross has confirmed that the shortage for Teva-Budesonide 0.125 mg/ml Inhalation Suspension (DIN 02465949) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 2, 2024**. The following grouping was removed from the Critical Supply Product List March 1, 2024.

BUDESONIDE

0.125 MG / ML INHALATION SUSPENSION

00002494264	TARO- BUDESONIDE	TAR	\$ 0.1143
00002465949	TEVA-BUDESONIDE	TEV	\$ 0.1143
00002229099	PULMICORT NEBUAMP	AZC	\$ 0.2493

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

